United Kingdom Polycystic Ovarian Syndrome Market Insight
United Kingdom Polycystic Ovarian Syndrome Market is growing at an 3.8% CAGR, riven by rising PCOS prevalence, fertility treatments
United Kingdom Polycystic Ovarian Syndrome Market Insights Forecasts to 2035
- The United Kingdom Polycystic Ovarian Syndrome Market Size Was Estimated at USD 147.9 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 3.8% from 2025 to 2035
- The United Kingdom Polycystic Ovarian Syndrome Market Size is Expected to Reach USD 214.8 Million by 2035
Notable Insights for United Kingdom Polycystic Ovarian Syndrome Market
- By treatment type, hormonal therapy dominated, accounting for approximately 52% share in 2024, driven by widespread use of oral contraceptives and anti-androgen medications.
- By therapy category, insulin-sensitizing drugs held approximately 30% share, supported by increasing links between PCOS, obesity, and insulin resistance.
- Approximately 13% of women of reproductive age in the UK are affected by PCOS, though many cases remain undiagnosed due to symptom variability.
- Around 73% of diagnosed women undergo long-term hormonal or metabolic treatment to manage irregular menstruation, infertility, acne, and weight-related complications.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Polycystic Ovarian Syndrome Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Polycystic Ovarian Syndrome Market
- Bayer AG
- Merck KGaA
- Pfizer Inc.
- Abbott Laboratories
- Novartis AG
- Ferring Pharmaceuticals
- Organon
- Teva Pharmaceutical Industries
- Others
Recent Developments:
- In July 2025, UK healthcare providers increased off-label semaglutide use for PCOS management, supporting weight reduction, metabolic control, and improved insulin resistance among women with hormonal disorders.
- In May 2025, UK researchers expanded studies on semaglutide and AI-assisted diagnostics for PCOS, supporting improved metabolic management, fertility outcomes, and earlier hormonal disorder detection among women.
Market Segmentation:
United Kingdom Polycystic Ovarian Syndrome Market, By Treatment Type
- Hormonal Therapy
- Insulin-Sensitizing Agents
- Fertility Treatments
- Anti-Androgen Medications
- Others
United Kingdom Polycystic Ovarian Syndrome Market, By Route of Administration
- Oral
- Injectable
United Kingdom Polycystic Ovarian Syndrome Market, By End User
- Hospitals & Clinics
- Home Care Settings
- Fertility Centers
United Kingdom Polycystic Ovarian Syndrome Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The UK Polycystic Ovarian Syndrome Market is expected to grow steadily due to increasing awareness of hormonal disorders, rising infertility concerns, and improved diagnostic accessibility. Experts emphasize that hormonal therapies and insulin-sensitizing treatments will continue dominating the market because of their effectiveness in symptom management. Expanding NHS women’s health programs, advancements in fertility treatments, and ongoing research into metabolic and endocrine therapies are anticipated to support long-term market growth and improve patient outcomes through 2035.